Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement

The dismal outcome of pleuropericardial extramedullary multiple myeloma (EMM) reflects both the selection of resistant disease and absence of useful drugs. Carfilzomib and dexamethasone should be explored in advanced EMM patients, even for bortezomib‐resistant patients, as may provide much longer ov...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Case Rep
Prif Awduron: Español, Ignacio, Romera, Marta, Gutiérrez‐Meca, María Dolores, García, Maria del Carmen, Tejedor, Aurelia, Martínez, Antonio, Ibáñez, Jerónima, De Arriba, Felipe, Minguela, Alfredo, Iturbe, Teodoro, López, Maria Dolores
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2017
Pynciau:
Case Reports
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5538069/
https://ncbi.nlm.nih.gov/pubmed/28781837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.1015
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg